![]() |
|
|
Vol. 290, Issue 3, 1442-1457, September 1999
Laboratory of Experimental Surgery (H.B.-B., Z.H., R.L., M.C.,
Z.S., B.Y.K.), Unit for Molecular Biology, Human papilloma virus 16 (HPV16) is considered to be the
causative agent for cervical cancer, which ranks second to breast cancer in women's malignancies. In an attempt to develop drugs that
inhibit the malignant transformation of HPV16-immortalized epithelial
cells, we examined the effect of tyrphostins on such cells. We examined
the effect of tyrphostins from four different families on the growth of
HPV16-immortalized human keratinocytes (HF-1) cells. We found that they
alter their cell cycle distribution, their morphology, and induce cell
death by apoptosis. The effects of tyrphostins on HF-1 cells are
different from their effects on normal keratinocytes. Growth
suppression by AG555 and AG1478 is accompanied by 30% apoptosis
in HF-1 cells, but this is not observed in normal keratinocytes.
Tyrphostin treatment produces distinctive morphological changes in HF-1
cells and in normal keratinocytes; however, the culture organization of
normal keratinocytes is less disrupted. These differential effects of
the tyrphostins on HPV16-immortalized keratinocytes compared with their
effects on normal keratinocytes suggests that these compounds are
suitable candidates for the treatment of papilloma. Previous and
present results indicate that group 1 tyrphostins, which inhibit Cdk2 activation, and group 2 tyrphostins, represented by AG1478, a potent
epidermal growth factor receptor kinase inhibitor, induce cell
cycle arrest; and, in the case of HF-1 cells, apoptosis and differentiation. Cells accumulate in the G1 phase of the
cell cycle at the expense of S and G2 + M. These compounds
block the growth of normal keratinocytes without inducing apoptosis or
differentiation, causing them to accumulate in G1. AG17,
which belongs to group 4, exerts its antiproliferative effect mainly by
increasing the fractions of cells in G1 with a
concomitant decrease in the fraction of cells in S and G2 + M.
0022-3565/99/2903-1442$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
S. M. Khan, R. H. Oliver, and J. Yeh Epidermal Growth Factor Receptor Inhibition by Tyrphostin 51 Induces Apoptosis in Luteinized Granulosa Cells J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 469 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baars, A. Bachmann, A. Levitzki, and F. Rosl Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function J. Biol. Chem., September 26, 2003; 278(39): 37306 - 37313. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Johnston, J. W. Barrett, W. Chang, C.-S. Chung, W. Zeng, J. Masters, M. Mann, F. Wang, J. Cao, and G. McFadden Role of the Serine-Threonine Kinase PAK-1 in Myxoma Virus Replication J. Virol., May 15, 2003; 77(10): 5877 - 5888. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sabri, J. Guo, H. Elouardighi, A. L. Darrow, P. Andrade-Gordon, and S. F. Steinberg Mechanisms of Protease-activated Receptor-4 Actions in Cardiomyocytes. ROLE OF Src TYROSINE KINASE J. Biol. Chem., March 21, 2003; 278(13): 11714 - 11720. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Hollenberg PARs in the stars: proteinase-activated receptors and astrocyte function. Focus on "Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways" Am J Physiol Cell Physiol, November 1, 2002; 283(5): C1347 - C1350. [Full Text] [PDF] |
||||
![]() |
C. D. Woodworth, D. Gaiotti, E. Michael, L. Hansen, and M. Nees Targeted Disruption of the Epidermal Growth Factor Receptor Inhibits Development of Papillomas and Carcinomas from Human Papillomavirus-immortalized Keratinocytes Cancer Res., August 1, 2000; 60(16): 4397 - 4402. [Abstract] [Full Text] |
||||